Characterizing upper limb function in the context of activities of daily living in CLN3 disease

被引:3
|
作者
Hildenbrand, Hanna [1 ]
Wickstrom, Jordan [1 ]
Parks, Rebecca [1 ]
Zampieri, Cris [1 ]
Nguyen, Thuy-Tien [1 ]
Thurm, Audrey [2 ]
Jenkins, Kisha [3 ]
Alter, Katharine E. [1 ]
Matsubara, Jesse [1 ]
Hammond, Dylan [3 ]
Soldatos, Ariane [4 ]
Porter, Forbes D. [3 ]
Dang Do, An N. [3 ]
机构
[1] NIH, Dept Rehabil Med, Ctr Clin, Bethesda, MD 20892 USA
[2] NIMH, Neurodev & Behav Phenotyping Serv, NIH, Bethesda, MD 20892 USA
[3] Eunice Kennedy Shriver Natl Inst Child Hlth & Hum, Off Clin Director, NIH, 10 Ctr Dr,Room 2-5132, Bethesda, MD 20892 USA
[4] NINDS, Pediat Neurol Consultat Serv, NIH, Bldg 36,Rm 4D04, Bethesda, MD 20892 USA
关键词
Batten; motor function; neuronal ceroid lipofuscinoses; occupational therapy; rehabilitation; LIPOFUSCINOSIS BATTEN-DISEASE; TEST-RETEST RELIABILITY; JEBSEN TAYLOR TEST; HAND FUNCTION; DISABILITY INVENTORY; PEDIATRIC EVALUATION; PHYSICAL-ACTIVITY; VISUAL IMPAIRMENTS; CHILDREN; PERFORMANCE;
D O I
10.1002/ajmg.a.62114
中图分类号
Q3 [遗传学];
学科分类号
071007 ; 090102 ;
摘要
In CLN3 disease, impairments in motor function are frequently reported to have later onset compared to visual and cognitive decline, but upper limb motor function has yet to be explored in this population. In a cohort of 22 individuals with CLN3, we used a novel application of multiple measures to (1) characterize motor function, particularly of the upper limbs, in activities of daily living (ADLs), and (2) explore associations between motor function and age as well as visual ability, disease severity, and cognitive function, as evaluated by the Unified Batten Disease Rating Scale (UBDRS), a validated CLN3 disease measure. ADLs that required coordination, speed, and fine motor control were particularly challenging for children with CLN3 based on item-level performance across direct assessments (Jebsen-Taylor Hand Function Test [JTHFT] and MyoSet Tools) and caregiver reports (Pediatric Evaluation of Disability Inventory-Computer Adaptive Testing [PEDI-CAT] and Patient-Reported Outcomes Measurement Information System [PROMIS] Pediatric Upper Extremity). Poorer visual ability, disease severity, and cognitive function were associated with worse performance on these measures, whereas age had limited impact. These findings support the need for children with CLN3 to receive skilled clinical evaluation and treatment tailored to their individual needs, particularly in the context of ADLs, as their symptom profile progresses.
引用
收藏
页码:1399 / 1413
页数:15
相关论文
共 50 条
  • [21] Kinematic descriptions of upper limb function using simulated tasks in activities of daily living after stroke
    Chen, Yen-Wei
    Liao, Wan-Wen
    Chen, Chia-Ling
    Wu, Ching-Yi
    HUMAN MOVEMENT SCIENCE, 2021, 79
  • [22] The effects of prism glasses and intensive upper limb exercise on hemineglect, upper limb function, and activities of daily living in stroke patients: a case series
    Oh, Se-Il
    Kim, Jin-Kyung
    Park, So-Yeon
    JOURNAL OF PHYSICAL THERAPY SCIENCE, 2015, 27 (12) : 3941 - 3943
  • [23] Loss of Cln3 Function in the Social Amoeba Dictyostelium discoideum Causes Pleiotropic Effects That Are Rescued by Human CLN3
    Huber, Robert J.
    Myre, Michael A.
    Cotman, Susan L.
    PLOS ONE, 2014, 9 (10):
  • [24] Diagnostic Confidence for CLN3 Disease (Juvenile Batten Disease)
    Masten, M.
    Vierhile, A.
    Vermilion, J.
    Adams, H.
    Zimmerman, G.
    Corre, C.
    Augustine, E.
    Mink, J.
    ANNALS OF NEUROLOGY, 2021, 90 : S160 - S160
  • [25] Genotype-phenotype associations in CLN3 disease
    Masten, Margaux C.
    Vierhile, Amy
    Vermilion, Jennifer
    Adams, Heather R.
    Augustine, Erika F.
    Mink, Jonathan W.
    MOLECULAR GENETICS AND METABOLISM, 2021, 132 (02) : S69 - S70
  • [26] Mitochondrial abnormalities in CLN2 and CLN3 forms of Batten disease
    Dawson, G
    Kilkus, J
    Siakotos, AN
    Singh, I
    MOLECULAR AND CHEMICAL NEUROPATHOLOGY, 1996, 29 (2-3) : 227 - 235
  • [27] Diagnostic Confidence for CLN3 Disease (Juvenile Batten Disease)
    Masten, Margaux C.
    Vierhile, Amy
    Vermilion, Jennifer
    Adams, Heather R.
    Zimmerman, Grace A.
    Corre, Camille
    Augustine, Erika F.
    Mink, Jonathan W.
    NEUROLOGY, 2021, 96 (15)
  • [28] Repurposing of tamoxifen ameliorates CLN3 and CLN7 disease phenotype
    Soldati, Chiara
    Lopez-Fabuel, Irene
    Wanderlingh, Luca G.
    Garcia-Macia, Marina
    Monfregola, Jlenia
    Esposito, Alessandra
    Napolitano, Gennaro
    Guevara-Ferrer, Marta
    Scotto Rosato, Anna
    Krogsaeter, Einar K.
    Paquet, Dominik
    Grimm, Christian M.
    Montefusco, Sandro
    Braulke, Thomas
    Storch, Stephan
    Mole, Sara E.
    De Matteis, Maria A.
    Ballabio, Andrea
    Sampaio, Julio L.
    McKay, Tristan
    Johannes, Ludger
    Bolanos, Juan P.
    Medina, Diego L.
    EMBO MOLECULAR MEDICINE, 2021, 13 (10)
  • [29] Nature of Batten disease CLN3 protein in brain
    Pullarkat, RK
    Pullarkat, PS
    Morris, GN
    JOURNAL OF NEUROCHEMISTRY, 1997, 69 : S193 - S193
  • [30] Mutations in CLN3 gene responsible of Batten disease
    Milà, M
    Mallolas, J
    Pineda, M
    Ferrer, I
    Vernet, A
    Badenas, C
    Sánchez, A
    Ballesta, F
    EUROPEAN JOURNAL OF HUMAN GENETICS, 1998, 6 : 145 - 145